ViroClinics Biosciences
ViroClinics Biosciences is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- A global amendment increased the planned eligible sample from 1500 to approximately 2510 because low global COVID-19 hospitalization and death rates reduced endpoint event rates.
- Rapid enrollment prevented the planned interim analysis after 65% of subjects completed Day 29 assessments; consequently, adolescent enrollment was not recommended and no pediatric subjects were enrolled.
- Of 218 screen failures, 177 were due to failure to meet entry criteria.
- Enrollment was concentrated in North America (1811/2285 subjects), whereas Europe enrolled 57 subjects, Asia 170 subjects, and other countries 247 subjects.
These findings describe the trial, not the service provider’s performance or responsibility.
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available2 trial-level findings · Read insights
- Protocol Amendment 1 excluded SARS-CoV-2-positive participants because their inclusion could interfere with safety-data interpretation owing to similarities with influenza.
- Protocol Amendment 2 added daily body-weight assessment to improve dosing accuracy for population pharmacokinetic modelling.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
Sponsor Solid Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy
Sponsor Solid Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety, and Immunogenicity in Infants Born to Vaccinated Mothers.
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Global, Randomized, Modified Double-Blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine in Adults 60 Years of Age and Older.
Sponsor AstraZeneca AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase IIIb Multicenter, Single-Arm, Open-Label Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Patients with Influenza and Transmission of Influenza to Household Contacts
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications
Sponsor Enanta Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease
Sponsor Shionogi B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) Infection
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ViroClinics Biosciences?
The 2026-10-09 snapshot links ViroClinics Biosciences to 11 distinct CTIS trials. Recorded services include Laboratory services, AAV9 Antibody Testing, Biomarkers/ Specialty Labs, Immunogenicity Antibody Testing, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ViroClinics Biosciences?
The most frequently recorded therapeutic areas are Infectious Disease, Genetic and Congenital Disorders, Musculoskeletal, Neurology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ViroClinics Biosciences conducted?
The linked trials record locations in 16 countries, including Spain, Germany, Bulgaria, Italy, Poland. These are trial locations, not confirmed office locations or countries where ViroClinics Biosciences delivered services.
What can this page tell me about ViroClinics Biosciences's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under ViroClinics Biosciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ViroClinics Biosciences B.V.